tbuckley/cabot-search huggingface dataset:
TCT-311 4-Year Clinical Outcomes in High Bleeding Risk Patients After Surgical or Percutaneous Left Main Coronary Artery Revascularization: The EXCEL Trial
Authors: Bimmer Claessen, Gennaro Giustino, Ori Ben-Yehuda, David Taggart, David Kandzari, Marie-Claude Morice, Roxana Mehran, Annapoorna Kini, Paul Guedeney, A. Pieter Kappetein, Joseph Sabik, Patrick Serruys, Gregg Stone
Journal: Journal of the American College of Cardiology (2019)
TCT-588 Mid- and Long-Term Clinical Outcomes of Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation: Fractional Flow Reserve–Guided Versus Intravascular Ultrasound-Guided
Authors: Kounosuke Inoue, Shinjo Sonoda, Masaru Araki, Shoichi Kuramitsu, Takenori Domei, Takeshi Serikawa, Yutaka Otsuji
Journal: Journal of the American College of Cardiology (2019)
Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study
Authors: Lauren K Troy, Christopher Grainge, Tamera J Corte, Jonathan P Williamson, Michael P Vallely, Wendy A Cooper, Annabelle Mahar, Jeffrey L Myers, Simon Lai, Ellie Mulyadi, Paul J Torzillo, Martin J Phillips, Helen E Jo, Susanne E Webster, Qi T Lin, Jessica E Rhodes, Matthew Salamonsen, Jeremy P Wrobel, Benjamin Harris, Garrick Don, Peter J C Wu, Benjamin J Ng, Christopher Oldmeadow, Ganesh Raghu, Edmund M T Lau, David Arnold, Christopher Cao, Amy Cashmore, Shannon Cleary, Tiffany-Jane Evans, Bruce French, Monika Geis, Laura Glenn, Michael Hibbert, Alvin Ing, Allen James, Graham Meredith, Christopher Merry, Anand Pudipeddi, Tajalli Saghaie, Rajesh Thomas, Claire Thomson, Scott Twaddell
Journal: The Lancet Respiratory Medicine (2019)
CGM Initiation Soon After Type 1 Diabetes Diagnosis Results in Sustained CGM Use and Wear Time
Authors: Priya Prahalad, Ananta Addala, David Scheinker, Korey K. Hood, David M. Maahs
Journal: Diabetes Care (2019)

The majority of youth with type 1 diabetes are above hemoglobin A1c (HbA1c) targets. Continuous glucose monitoring (CGM) has been shown to improve clinical outcomes, and use early in the course of diabetes has the potential to improve glycemic outcomes and improve quality of life.

In our clinic, youth with new-onset type 1 diabetes were offered the opportunity to start on CGM (Dexcom G6) soon after diabetes diagnosis. Ongoing CGM coverage was subsequently applied for through the patient’s insurance. Following CGM initiation, youth had a 1-week follow-up with a nurse practitioner. Per clinic standard of care, youth were seen again at 1 month post-diagnosis and every 3 months thereafter. We prospectively collected data on HbA1c, continued CGM use, days of CGM wear, method of viewing CGM data, time in range (TIR), and time in hypoglycemia. Institutional review board approval was obtained for the prospective data collection.

From July 2018 to April 2019, we approached 44 youth with newly diagnosed type 1 diabetes to initiate CGM. Forty-one youth (at onset: mean age 9.7 ± 4.1 years, 56% male, 90% with private insurance, 41% non-Hispanic white, HbA1c 12.2 ± 1.8% [110 mmol/mol]) were started on CGM at a mean of 9.0 ± 8.8 days post–diabetes diagnosis (Table 1). Three adolescent youth declined CGM, stating they did …
Luminescent ruthenium(II) polypyridyl complexes acted as radiosensitizer for pancreatic cancer by enhancing radiation-induced DNA damage
Authors: Yuyang Zhou, Ying Xu, Lunjie Lu, Jingyang Ni, Jihua Nie, Jianping Cao, Yang Jiao, Qi Zhang
Journal: Theranostics (2019)

Background: Pancreatic cancer is a highly lethal malignancy which ranks 4th most common cause of cancer death in US and 6th in China.Novel drugs are required to improve the survival and prognosis of patients.Methods: Ruthenium(II) complexes with variation number of DIP ligand were synthesized and further adopted as radiosensitizer for pancreatic cancer.The influence of ruthenium(II) complexes on cell behaviors and tumor growth were investigated.The DNA binding affinity of ruthenium(II) complexes and plasmid was measured by using agarose gel electrophoresis.Results: Luminescent ruthenium(II) complex can rapidly enter into cell nuclei and consequently combine with DNA, resulting in the enhanced DNA damage induced by X-ray irradiation.Upon intratumoral injection of ruthenium(II) complex, excellent tumor growth inhibition was accomplished under ionizing radiation of human pancreatic cancer xenograft nude mice. Conclusions:Taken together, our study suggest that the ruthenium(II) polypyridyl complexes can effectively enhance radiation-induced DNA damage, which is likely to benefit the imaging-guided cancer radio-chemotherapy.
Multiple MLL fusion proteins suppress p53-mediated response to DNA damage
Authors: Dmitri Wiederschain, Hidehiko Kawai, Ali Shilatifard, Zhi-Min Yuan
Journal: Cancer Research (2004)

2618  Reciprocal chromosomal translocations involving the MLL (Mixed Lineage Leukemia) gene are frequently detected in acute leukemias of both myeloid and lymphocytic origin. It has been demonstrated that MLL fusions can mediate both malignant transformation of normal blood progenitors and subsequent onset of leukemia-like disease in animals. However, molecular mechanisms of MLL leukemogenesis are still poorly understood. We have recently demonstrated that MLL-ELL fusion protein is a potent inhibitor of p53 transcriptional activity, and that this inhibitory effect depends entirely on the presence of intact ELL C-terminus. In this study we investigated the effect of MLL-ELL and several additional frequently-detected MLL fusion proteins on p53 activity in response to genotoxic stress. To accomplish this, expression constructs encoding MLL-AF9, MLL-AF10, MLL-ENL and MLL-ELL were introduced into wild-type p53 U2OS and HCT116 cells using a retroviral gene delivery system. In addition, we generated HCT116 cells that expressed truncated MLL-ELL (MLL-ELLΔCT) incapable of suppressing p53 activity. The presence of MLL fusions in all cell lines was confirmed by RT-PCR and, in the case of MLL-ELL and its truncated mutant, by Western blot using anti-ELL antibodies. Next we challenged MLL fusion-expressing cells with various doses of either ionizing radiation (IR) or adriamycin; and then monitored the induction of endogenous p53 and its direct transcriptional targets. Following exposure to IR or adriamycin, p53 protein levels increased over time to comparable levels in all cell lines. The induction of endogenous p21, MDM2 and Bax was severely diminished in cells expressing full-length MLL fusion proteins, but not in Vector- or MLL-ELLΔCT-expressing cells. These data indicate that stable expression of MLL fusion proteins results in reduced p53 activity in response to a variety of stress signals. In order to increase the biological relevance of our findings to leukemic disease, we retrovirally transduced TK6 lymphoblastic leukemia cells, which express functional wild-type p53, with MLL fusions and treated these cells with either IR or 5-fluorouracil (5-FU). Despite a significant increase in p53 protein abundance following exposure to IR, TK6 cells expressing MLL-AF9, MLL-AF10, MLL-ENL and MLL-ELL exhibited reduced upregulation of p21 when compared with Vector or MLL-ELLΔCT-expressing cells. Apoptosis in response to 5-FU treatment was also dampened in full-length MLL fusion-expressing cells. Collectively our data show for the first time that frequently observed MLL leukemogenic fusion proteins interfere with cellular response to genotoxic stress by suppressing the activity of p53. Furthermore, our results demonstrate that the presence of intact MLL partner protein is required for the inhibitory effect of MLL chimeras on p53. Our results suggest that abrogation of p53 functional activity can be a common feature of MLL leukemogenesis.
TCT-25 Comparative Safety and Effectiveness of Orbital and Rotational Atherectomy in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)
Authors: Devika Aggarwal, Milan Seth, Emily Perdoncin, Theodore Schreiber, Amir Kaki, Khaldoon Alaswad, Daniel Menees, Devraj Sukul, Hitinder Gurm
Journal: Journal of the American College of Cardiology (2019)
TCT-752 Incidence and Outcomes of Patient-Prosthesis Mismatch Following Self-Expanding Transcatheter Aortic Valve Replacement: An Analysis From the STS/ACC TVT Registry
Authors: Gilbert Tang, Vinayak Bapat, Jeffrey Popma, David H. Adams, Susheel Kodali, Basel Ramlawi, Hemal Gada, John Forrest, Ryan Kaple, Michael Reardon
Journal: Journal of the American College of Cardiology (2019)
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Authors: Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Morihito Okada, Chen-Yuan Lin, Keisho Chin, Shigenori Kadowaki, Myung-Ju Ahn, Yasuo Hamamoto, Yuichiro Doki, Chueh-Chuan Yen, Yutaro Kubota, Sung-Bae Kim, Chih-Hung Hsu, Eva Holtved, Ioannis Xynos, Mamoru Kodani, Yuko Kitagawa
Journal: The Lancet Oncology (2019)
TCT-20 Aortic Root Anatomy in Low-Risk Patients After Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: Impact on Coronary Access and Repeat Aortic Valve Interventions
Authors: Toby Rogers, Michael Fuery, Jaffar Khan, Paige Craig, Rebecca Torguson, Cheng Zhang, Gaby Weissman, Federico Asch, Christian Shults, Lowell Satler, Ron Waksman
Journal: Journal of the American College of Cardiology (2019)
TCT-279 Safety and Efficacy of Sirolimus-Eluting Stent System in All-Comers Real-World Population With Coronary Artery Stenosis: The MILES-Global Study
Authors: Martin Hudec, Alexander Ijsselmuiden, Ramiro Trillo, Hyeon-Cheol Gwon, José Marques da Costa, In Ho Chae, Jose Moreu Burgos, Myung Ho Jeong, G. Mayurathan, Min-Ji Charng, Yi-Chih Wang, Oteh Maskon, Bela Merkely, Antonio Serra, Rita Theotonio, Andriy Khokhlov, Hristo Mateev, Chun Yao Huang, Philip Mar
Journal: Journal of the American College of Cardiology (2019)
Unrecognized Obstructive Sleep Apnea in Patients Undergoing Surgery
Authors: Peter Santer, Matthias Eikermann
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
US Dietary Guidance—Is It Working?
Authors: Linda Van Horn, Marilyn C. Cornelis
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leukemic Stem Cells Co-Opt Normal Bone Marrow Niches As a Source of Energy and Antioxidant Defence
Authors: Dorian Forte, María García-Fernández, Abel Sánchez-Aguilera, Vaya Stavropoulou, Claire Fielding, Daniel Martín-Pérez, Alexandar Tzankov, Juerg Schwaller, Simón Méndez-Ferrer
Journal: Blood (2017)
TCT-268 Midterm Clinical Outcomes Post–Sirolimus-Coated Balloon Angioplasty in Patients With Coronary Artery Disease: Single Center Experience
Authors: Sandeep Basavarajaiah, Ishaq Mohammed, Sampath Athukorala, Handi Salim, Richard Watkin, Gurbir Bhatia, Jerome Ment, Kaeng Lee, Michael Pitt, George Pulikal, Bethan Freestone
Journal: Journal of the American College of Cardiology (2019)
FRI0018 Protection by phosphodiesterase-4 inhibitor roflumilast of mice against collagen-induced arthritis
Authors: J Barsig, B Leung, DS Bundschuh, L Wollin, R Beume, FY Liew
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Orally available small molecular weight compounds with ability to suppress the proinflammatory mediator Tumour Necrosis Factor alpha (TNF) are of high interest for the treatment of rheumatoid arthritis (RA). Roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]-benzamide) is a highly potent and selective inhibitor of phosphodiesterase type 4 (PDE4), that effectively suppresses TNF production <i>in vitro</i> and <i>in vivo</i>.<sup>1,2</sup> This compound is currently in clinical development for asthma and COPD. <h3>Objectives</h3> We investigated the capacity of Roflumilast to reduce the release of TNF <i>in vivo</i> in mice, and also examined its antiarthritic potential in murine collagen-induced arthritis (CIA). <h3>Methods</h3> For induction of systemic TNF release, male BALB/c mice were injected intraperitoneally with lipopolysaccharide (LPS, S. abortus equi, 5 mg/kg). Mice were orally treated with 1 or 10 mg/kg of Roflumilast 30 min prior to LPS challenge. Plasma was obtained 90 min after challenge for determination of cytokines by ELISA. CIA was induced in male DBA/1 mice by intradermal injection of 200 μg of type II collagen (CII) in Freund?s complete adjuvant, followed by a booster injection of CII on day 21 (200 μg in PBS i.p.). Roflumilast (1 or 5 mg/kg) was given once daily p.o. on days 23‑33. Arthritic scores (0‑3) and paw thicknesses were monitored between days 21‑39. In parallel experiments, groups of mice were sacrificed and cells from draining lymph nodes were restimulated <i>in vitro</i> with graded concentrations of CII. TNF, Interleukin-6 (IL-6), and Interferon-gamma (IFN), released within 72 h of <i>in vitro</i> culture, were measured by ELISA. Histological analysis was performed on joints taken on day 35 after primary immunisation. <h3>Results</h3> Roflumilast dose-dependently suppressed LPS-induced TNF production <i>in vivo</i> (75% with 10 mg/kg). By contrast, plasma levels of the anti-inflammatory cytokine Interleukin-10 were substantially raised (500% with 10 mg/kg). In addition, Roflumilast dose-dependently protected mice against CIA. This was also evident histologically by a significant reduction of joint inflammation and bone/cartilage erosion. The <i>in vitro</i> capacity of lymph node cells to produce TNF, IL-6, and IFN upon CII-stimulation was markedly reduced, even when cells were prepared one week after withdrawal of drug treatment. <h3>Conclusion</h3> These data demonstrate that Roflumilast is a promising candidate for the oral treatment of rheumatoid arthritis. <h3>References</h3> Bundschuh DS, <i>et al</i>. J Pharmacol Exp Ther., in press Hatzelmann A, <i>et al</i>. J Pharmacol Exp Ther., in press
My Grandmother, the Doctor
Authors: Nathaniel P. Morris
Journal: Annals of Internal Medicine (2019)

On Being a Doctor1 October 2019My Grandmother, the DoctorNathaniel P. Morris, MDNathaniel P. Morris, MDStanford University School of Medicine, Stanford, California (N.P.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M19-0345 Audio Reading - “My Grandmother, the Doctor” Audio. Virginia Hood, MD, reads “My Grandmother, the Doctor” by Nathaniel P. Morris, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Last year, U.S. medicine lost a trailblazer. Most patients and clinicians have probably never heard of her. She didn't discover a new disease or invent a breakthrough therapy. Still, she was one of the earliest female doctors in the United States. And she was my grandmother.Born in 1925, Iris Smith grew up in a time when doctors were men. Her father was a physician who saw patients in the family's Brooklyn home, and her mother helped him run his practice. As a child, my grandmother sat in and listened to patient visits. One patient was a drama teacher who ... Author, Article, and Disclosure InformationAffiliations: Stanford University School of Medicine, Stanford, California (N.P.M.)Corresponding Author: Nathaniel P. Morris, MD, 401 Quarry Road, Stanford, CA 94304; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “My Grandmother, the Doctor” Audio. Virginia Hood, MD, reads “My Grandmother, the Doctor” by Nathaniel P. Morris, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 1 October 2019Volume 171, Issue 7Page: 518KeywordsChildrenPatientsPsychiatry and mental healthPsychologyResearch laboratoriesResidencyShockStrokeTouchWheelchairs ePublished: 1 October 2019 Issue Published: 1 October 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
TCT-776 Secondary Prevention of Ischemic Stroke Following Cryptogenic Stroke in Patients With Patent Foramen Ovale: A Meta-Analysis of Randomized Controlled Trials
Authors: Babikir Kheiri, Harsh Golwala, Mohammed Osman, Qais Radaideh, Khidir Dalouk, Eric Stecker, Firas Zahr, Babak Nazer, Hind Rahmouni
Journal: Journal of the American College of Cardiology (2019)
TCT-407 Adherence to Dual Antiplatelet Therapy and Long-Term Outcome of Drug-Eluting or Bare-Metal Stents: A Korean Nationwide Longitudinal Real-World Cohort Study
Authors: Jin-Ho Choi, Jung Min Choi, Seung Hwa Lee, Joo Myung Lee, Taek Kyu Park, Jeong Hoon Yang, Young Bin Song, Joo-Yong Hahn, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Sang-Hoon Lee
Journal: Journal of the American College of Cardiology (2019)
In Acute Trauma Care, Time Matters but Is Not Everything
Authors: Marc Maegele
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
SPED Statement: Training in Gastrointestinal Endoscopy
Authors: C Rolanda, F Vilas-Boas, L Eliseu
Journal: Endoscopy (2019)

Gastrointestinal endoscopy (GIE) depends on the operator’s competence. The acquisition of the technical dexterity and the cognitive integrative skills needed for its performance rely on several factors, and ultimately on the success of the GI endoscopy learning/training process.
Evaluating PAD Requests in Psychiatry: The Importance of Involving Others
Authors: Suzanne Metselaar, Gerben Meynen, Yolande Voskes, Guy Widdershoven
Journal: The American Journal of Bioethics (2019)

Kious and Battin (2019) explore the tension between physician-assisted dying (PAD) and prevention of suicide in psychiatry, and argue for the need for standards by which the severity of a person’s ...
European Society of Gastrointestinal Endoscopy (ESGE) curricula development for postgraduate training in advanced endoscopic procedures: rationale and methodology
Authors: Raf Bisschops, Evelien Dekker, James E. East, Gavin Johnson, Pedro Pimentel-Nunes, David S. Sanders, Mario Dinis-Ribeiro, Thierry Ponchon
Journal: Endoscopy (2019)

Corrected by:Correction: European Society of Gastrointestinal Endoscopy (ESGE) curricula development for postgraduate training in advanced endoscopic procedures: rationale and methodologyEndoscopy 2019; 51(10): C6-C6DOI: 10.1055/a-1031-7261
Attention Deficit–Hyperactivity Disorder in Children and Adolescents
Journal: New England Journal of Medicine (2014)

Introduction
Prevalence estimates of attention deficit hyperactivity disorder (ADHD) vary according to the diagnostic criteria used and the population sampled. DSM-5 prevalence estimate among school children in the US is 5%, but other estimates vary from 2% to 16%. No objective test exists to confirm the diagnosis of ADHD, which remains a clinical diagnosis. Other conditions frequently co-exist with ADHD.